Roth Capital Comments on BioDelivery Sciences International, Inc.’s Q1 2017 Earnings (BDSI)

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) – Roth Capital issued their Q1 2017 earnings per share (EPS) estimates for shares of BioDelivery Sciences International in a note issued to investors on Tuesday, Zacks Investment Research reports. Roth Capital analyst S. Henry expects that the specialty pharmaceutical company will post earnings per share of $0.09 for the quarter. Roth Capital currently has a “Buy” rating and a $5.00 target price on the stock. Roth Capital also issued estimates for BioDelivery Sciences International’s Q2 2017 earnings at ($0.24) EPS, Q3 2017 earnings at ($0.23) EPS, Q4 2017 earnings at ($0.21) EPS, FY2017 earnings at ($0.59) EPS and FY2018 earnings at ($0.55) EPS.

Several other analysts also recently issued reports on BDSI. Zacks Investment Research upgraded BioDelivery Sciences International from a “sell” rating to a “buy” rating and set a $2.00 price objective on the stock in a research report on Tuesday, January 10th. Cantor Fitzgerald set a $3.00 target price on BioDelivery Sciences International and gave the stock a “hold” rating in a research report on Tuesday, January 17th. FBR & Co set a $5.00 target price on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Thursday, February 2nd. Finally, Janney Montgomery Scott reiterated a “buy” rating and set a $3.00 target price on shares of BioDelivery Sciences International in a research report on Monday, March 20th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. BioDelivery Sciences International currently has a consensus rating of “Hold” and a consensus target price of $3.50.

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.chaffeybreeze.com/2017/04/20/biodelivery-sciences-international-inc-expected-to-earn-q1-2017-earnings-of-0-09-per-share-bdsi-updated-updated.html.

BioDelivery Sciences International (NASDAQ:BDSI) traded up 3.12% during midday trading on Thursday, reaching $1.65. 185,052 shares of the company were exchanged. BioDelivery Sciences International has a 52-week low of $1.50 and a 52-week high of $3.78. The company has a 50 day moving average of $1.88 and a 200-day moving average of $1.96. The company’s market capitalization is $90.41 million.

BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings results on Friday, March 17th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.03. BioDelivery Sciences International had a negative net margin of 93.61% and a negative return on equity of 309.49%. The company earned $3.90 million during the quarter, compared to analyst estimates of $6.37 million. During the same period in the prior year, the business posted $0.19 EPS. BioDelivery Sciences International’s revenue was down 87.9% compared to the same quarter last year.

In other news, CEO Mark A. Sirgo sold 110,895 shares of the firm’s stock in a transaction dated Friday, March 31st. The stock was sold at an average price of $1.90, for a total value of $210,700.50. Following the transaction, the chief executive officer now directly owns 1,670,157 shares in the company, valued at approximately $3,173,298.30. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders sold 119,250 shares of company stock worth $226,644. Company insiders own 9.00% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Stonepine Capital Management LLC purchased a new position in BioDelivery Sciences International during the fourth quarter worth approximately $4,551,000. GSA Capital Partners LLP purchased a new position in BioDelivery Sciences International during the fourth quarter worth approximately $142,000. Acadian Asset Management LLC purchased a new position in BioDelivery Sciences International during the third quarter worth approximately $217,000. Searle & CO. increased its position in BioDelivery Sciences International by 27.1% in the fourth quarter. Searle & CO. now owns 234,100 shares of the specialty pharmaceutical company’s stock worth $410,000 after buying an additional 49,850 shares during the period. Finally, Oxford Asset Management increased its position in BioDelivery Sciences International by 280.8% in the fourth quarter. Oxford Asset Management now owns 107,945 shares of the specialty pharmaceutical company’s stock worth $189,000 after buying an additional 79,599 shares during the period. Institutional investors own 53.57% of the company’s stock.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

5 Day Chart for NASDAQ:BDSI

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply